Trial Profile
Post-authorisation Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Risk of Acute Liver Injury, Acute Kidney Injury and Chronic Kidney Disease, Severe Complications of Urinary Tract Infection, Genital Infections, and Diabetic Ketoacidosis Among Patients Treated With Empagliflozin Compared to Patients Treated With DPP-4 Inhibitors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 02 Aug 2022 Status changed from active, no longer recruiting to completed.
- 29 Jul 2021 Planned End Date changed from 1 Aug 2021 to 1 Aug 2022.
- 29 Jul 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2022.